Johnson & Johnson (JNJ)vsMiMedx Group Inc (MDXG)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
MDXG
MiMedx Group Inc
$3.36
+8.91%
HEALTHCARE · Cap: $458.33M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 22918% more annual revenue ($96.36B vs $418.63M). JNJ leads profitability with a 21.8% profit margin vs 11.6%. MDXG appears more attractively valued with a PEG of 2.88. MDXG earns a higher WallStSmart Score of 74/100 (B).
JNJ
Buy59
out of 100
Grade: C
MDXG
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Intrinsic value data unavailable for MDXG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Attractively priced relative to earnings
Earnings expanding 99.5% YoY
Every $100 of equity generates 22 in profit
Reasonable price relative to book value
Revenue surging 27.1% year-over-year
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Smaller company, higher risk/reward
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : MDXG
The strongest argument for MDXG centers on P/E Ratio, EPS Growth, Return on Equity. Revenue growth of 27.1% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : MDXG
The primary concerns for MDXG are Market Cap, PEG Ratio.
Key Dynamics to Monitor
JNJ profiles as a mature stock while MDXG is a growth play — different risk/reward profiles.
MDXG carries more volatility with a beta of 1.65 — expect wider price swings.
MDXG is growing revenue faster at 27.1% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
MDXG scores higher overall (74/100 vs 59/100) and 27.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →MiMedx Group Inc
HEALTHCARE · BIOTECHNOLOGY · USA
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?